EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients

Zhigang Zheng iD, Huimin Wu, Xiaowei Sun, Yefeng Lu, Yanyan Song, Yi Luo, Tao Zhou, Mingxuan Feng, Ping Wan, Jianjun Zhu, Nan Shen, Qing Cao und 3 weitere

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Zhigang Zheng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, Liver Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Innovation Research Project as part of the Shanghai Science and Technology Innovation Action Plan, Shanghai Science and Technology Innovation Action Plan for 2021.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amidst the COVID‐19 pandemic, uncertainty persists among caregivers regarding the vaccination of pediatric liver transplant recipients (PLTRs). This study evaluates the immunogenicity and safety of COVID‐19 vaccination in this vulnerable population. A cohort of 30 PLTRs underwent sequential vaccinations with an inactivated SARS‐CoV‐2 vaccine followed by an Ad5‐nCoV booster. We collected and analyzed blood samples pre‐vaccination and four weeks post‐vaccination to quantify antibody and IGRA (IFN‐γ Release Assay) levels. We also documented any adverse reactions occurring within seven days post‐vaccination and monitored participants for infections over six months post‐vaccination, culminating in a comprehensive statistical analysis. The Ad5‐nCoV booster substantially elevated IgG (T1: 18.01, 20%; T2: 66.61, 55%) and nAb (T1: 119.29, 8%; T2: 3799.75, 80%) levels, as well as T‐cell responses, in comparison to the initial dose. The first dose was associated with some common adverse reactions, such as injection site pain (13.3%) and fever (16.6%), but a low rate of systemic reactions (16.0%). There was no significant difference in Omicron infection rates or RTPCR conversion times between vaccinated and unvaccinated groups. Notably, following Omicron infection, vaccinated individuals exhibited significantly higher SARS‐CoV‐2 IgG and nAb titers (average IgG: 231.21 vs. 62.09 S/CO, p = 0.0003; nAb: 5246.11 vs. 2592.07 IU/mL, p = 0.0002). The use of inactivated vaccines followed by an Ad5‐nCoV booster in PLTRs is generally safe and elicits a robust humoral response, albeit with limited T‐cell responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Liver TransplantationHumansChildCOVID-19 VaccinesPandemicsSARS-CoV-2Antibodies, ViralImmunoglobulin GVaccines, InactivatedAntibodies, NeutralizingVaccination

Stichwörter der Autor:innen

Ad5‐nCoVOmicronnebulized inhalation vaccinepediatric liver transplantation

Substanzen

COVID-19 VaccinesAntibodies, ViralImmunoglobulin GVaccines, InactivatedAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Clinical Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Biostatistics, Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Infectious Disease, Shanghai Children's Medical Center, National Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Shanghai Children's Medical Center-bioMérieux Laboratory, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • bioMérieux (Shanghai) Company Limited, Shanghai, China.

ORCID-Profile: Zhigang Zheng

Förderung

  • National Natural Science Foundation of China
  • Medical Innovation Research Project as part of the Shanghai Science and Technology Innovation Action Plan
  • Shanghai Science and Technology Innovation Action Plan for 2021
  • Renji Hospital Clinical Research Innovation and Cultivation Fund

Zitieren

APA

Zheng, Z., Wu, H., Sun, X., Lu, Y., Song, Y., Luo, Y., Zhou, T., Feng, M., Wan, P., Zhu, J., Shen, N., Cao, Q., Liang, J., Xia, Q., & Xue, F. (2024). Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients. Journal of Medical Virology. https://doi.org/10.1002/jmv.29543

Vancouver

Zheng Z, Wu H, Sun X, Lu Y, Song Y, Luo Y, et al. Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients. Journal of Medical Virology. 2024. doi:10.1002/jmv.29543

BibTeX
@article{Zheng2024,
  author = {Zheng, Zhigang and Wu, Huimin and Sun, Xiaowei and Lu, Yefeng and Song, Yanyan and Luo, Yi and Zhou, Tao and Feng, Mingxuan and Wan, Ping and Zhu, Jianjun and Shen, Nan and Cao, Qing and Liang, Ji and Xia, Qiang and Xue, Feng},
  title = {Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29543}
}
Kostenlos starten →